# First Year Growth Response Associated Genetic Markers Validation Phase IV Open-label Study in Growth Hormone Deficient and Turner Syndrome Pre-pubertal Children: the PREDICT Pharmacogenetics Validation Study

> **NCT01419249** · PHASE4 · COMPLETED · sponsor: **Merck KGaA, Darmstadt, Germany** · enrollment: 458 (actual)

## Conditions studied

- Idiopathic Growth Hormone Deficiency
- Turner Syndrome

## Interventions

- **OTHER:** Blood sampling

## Key facts

- **NCT ID:** NCT01419249
- **Lead sponsor:** Merck KGaA, Darmstadt, Germany
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-09
- **Primary completion:** 2012-10
- **Final completion:** 2012-10
- **Target enrollment:** 458 (ACTUAL)
- **Last updated:** 2014-01-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01419249

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01419249, "First Year Growth Response Associated Genetic Markers Validation Phase IV Open-label Study in Growth Hormone Deficient and Turner Syndrome Pre-pubertal Children: the PREDICT Pharmacogenetics Validation Study". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01419249. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*